992. Role of Cerebrospinal Fluid Enzyme Immunoassay (EIA) in the Diagnosis of Neurosyphilis
Session: Poster Abstract Session: Diagnostic Microbiology: Quality Improvement and Rapid Diagnostics
Friday, October 9, 2015
Room: Poster Hall
  • Role of CSF EIA in the diagnosis of neurosyphilis.pdf (406.9 kB)
  • Background: There is currently no single reliable method for the diagnosis of neurosyphilis. The reported sensitivity of reactive cerebrospinal fluid venereal disease research laboratory (CSF-VDRL) test is only around 50%.

    Methods: : A retrospective review of 18 cerebrospinal fluid (CSF) specimens submitted for CSF-VDRL analysis from October 2014 to May 2015 in patients suspected to have neurosyphilis was conducted. The feasibility of using EIA in place of CSF-VDRL was evaluated.

    Results: Eighteen CSF specimens were  included in the review. Thirteen (13) CSF were negative for CSF-VDRL and EIA. One CSF had a CSF-VDRL titer of 1:8; EIA was strongly positive at an index of 42.7. Four CSF specimens were negative for CSF-VDRL; all 4 specimens were positive for EIA with an index of 6.8, 12.2, 13.0 and 56.0. EIA index of <0.9 was considered negative; 0.9-1.09 was equivocal, and >1.1 was reported as positive.

    Conclusion: These results show that EIA may be more sensitive than CSF-VDRL in the diagnosis of neurosyphilis. Further studies are ongoing to validate the use of EIA for the diagnosis of neurosyphilis.

    Eunice Ann Wong, MD1, Milagros Reyes, MD, FIDSA2, Patrick Long, PhD3 and Hollie Webb, MT3, (1)Infectious Diseases, Detroit Medical Center-Wayne State University, Detroit, MI, (2)Infectious Diseases, Wayne State University/Detroit Medical Center, Detroit, MI, (3)Detroit Medical Center - Wayne State University, Detroit, MI


    E. A. Wong, None

    M. Reyes, None

    P. Long, None

    H. Webb, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.